Research Article
Breast cancer and family history for breast cancer in patients with differentiated thyroid carcinoma
Abstract
Purpose: The risk for breast cancer in
patients with thyroid cancer has been investigated in previous studies, and has
been found to be increased. In this study, we present a retrospective analysis
of patients with differentiated thyroid carcinoma in respect to breast cancer
and family history of breast cancer.
Methods:
We conducted a
retrospective study involving 455 patients who were diagnosed as having
differentiated thyroid carcinoma between January 2009 and March 2016.
Results: The majority of the patents were
female (403, 88.6 %). The mean age at diagnosis was 45.5 ± 12.8 years (range,
10-81 years). We detected that 0.7 % patients with thyroid cancer had breast
cancer and 13.4 % patients had a family history of breast cancer within 3
generations of the proband. There were no significant differences between
family history of breast cancer and sex, age at diagnosis, pathologic types,
and radioiodine therapy.
Conclusion: In the literature, there are many
clinical, epidemiologic, and experimental studies that show an association
between thyroid cancer and breast cancer. Our study
is the first report to show history of breast cancer and family history of
breast cancer as 0.7 % and 13.4 % in this particular group of Turkish patients
with differentiated thyroid cancer.
Keywords
References
- 1. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. The oncologist. 2007; 12:20-37.2. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009; 115:3801-7.3. Garner CN, Ganetzky R, Brainard J, et al. Increased prevalence of breast cancer among patients with thyroid and parathyroid disease. Surgery. 2007; 142:806-13; discussion 13 e1-3.4. Joseph KR, Edirimanne S, Eslick GD. The association between breast cancer and thyroid cancer: a meta-analysis. Breast cancer research and treatment. 2015; 152:173-81.5. Vassilopoulou-Sellin R, Palmer L, Taylor S, Cooksley CS. Incidence of breast carcinoma in women with thyroid carcinoma. Cancer. 1999; 85:696-705.6. Kuo JH, Chabot JA, Lee JA. Breast cancer in thyroid cancer survivors: An analysis of the Surveillance, Epidemiology, and End Results-9 database. Surgery. 2016; 159:23-9.7. An JH, Hwangbo Y, Ahn HY, et al. A Possible Association Between Thyroid Cancer and Breast Cancer. Thyroid : official journal of the American Thyroid Association. 2015; 25:1330-8.8. Subramanian S, Goldstein DP, Parlea L, et al. Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid : official journal of the American Thyroid Association. 2007; 17:1277-88.9. Goldman MB, Maloof F, Monson RR, Aschengrau A, Cooper DS, Ridgway EC. Radioactive iodine therapy and breast cancer. A follow-up study of hyperthyroid women. American journal of epidemiology. 1988; 127:969-80.10. Ron E, Curtis R, Hoffman DA, Flannery JT. Multiple primary breast and thyroid cancer. British journal of cancer. 1984; 49:87-92.11. Kumar A, Klinge CM, Goldstein RE. Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta. International journal of oncology. 2010; 36:1067-80.12. Vivacqua A, Bonofiglio D, Albanito L, et al. 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30. Molecular pharmacology. 2006; 70:1414-23.13. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. The Journal of clinical endocrinology and metabolism. 2008; 93:504-15.14. Consorti F, Di Tanna G, Milazzo F, Antonaci A. Nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer. World journal of surgical oncology. 2011; 9:88.15. Zhang L, Wu Y, Liu F, Fu L, Tong Z. Characteristics and survival of patients with metachronous or synchronous double primary malignancies: breast and thyroid cancer. Oncotarget. 2016.16. Tanaka H, Tsukuma H, Koyama H, Kinoshita Y, Kinoshita N, Oshima A. Second primary cancers following breast cancer in the Japanese female population. Japanese journal of cancer research : Gann. 2001; 92:1-8.17. Evans HS, Lewis CM, Robinson D, Bell CM, Moller H, Hodgson SV. Incidence of multiple primary cancers in a cohort of women diagnosed with breast cancer in southeast England. British journal of cancer. 2001; 84:435-40.18. Nielsen SM, White MG, Hong S, et al. The Breast-Thyroid Cancer Link: A Systematic Review and Meta-analysis. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2016; 25:231-8.19. Yane K, Kitahori Y, Konishi N, et al. Expression of the estrogen receptor in human thyroid neoplasms. Cancer letters. 1994; 84:59-66.20. Manole D, Schildknecht B, Gosnell B, Adams E, Derwahl M. Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. The Journal of clinical endocrinology and metabolism. 2001; 86:1072-7.21. Gogas J, Kouskos E, Tseleni-Balafouta S, et al. Autoimmune thyroid disease in women with breast carcinoma. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2001; 27:626-30.22. Hardefeldt PJ, Eslick GD, Edirimanne S. Benign thyroid disease is associated with breast cancer: a meta-analysis. Breast cancer research and treatment. 2012; 133:1169-77.23. Smyth PP. The thyroid, iodine and breast cancer. Breast cancer research : BCR. 2003; 5:235-8.24. Paes JE, Hua K, Nagy R, Kloos RT, Jarjoura D, Ringel MD. The relationship between body mass index and thyroid cancer pathology features and outcomes: a clinicopathological cohort study. The Journal of clinical endocrinology and metabolism. 2010; 95:4244-50.25. Fallahi B, Adabi K, Majidi M, et al. Incidence of second primary malignancies during a long-term surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment. Clinical nuclear medicine. 2011; 36:277-82.26. Lin CY, Lin CL, Huang WS, Kao CH. Risk of Breast Cancer in Patients with Thyroid Cancer Receiving or Not Receiving 131I Treatment: A Nationwide Population-Based Cohort Study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016; 57:685-90.
Year 2019,
Volume: 52 Issue: 1, 79 - 82, 14.03.2019
Abstract
References
- 1. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. The oncologist. 2007; 12:20-37.2. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009; 115:3801-7.3. Garner CN, Ganetzky R, Brainard J, et al. Increased prevalence of breast cancer among patients with thyroid and parathyroid disease. Surgery. 2007; 142:806-13; discussion 13 e1-3.4. Joseph KR, Edirimanne S, Eslick GD. The association between breast cancer and thyroid cancer: a meta-analysis. Breast cancer research and treatment. 2015; 152:173-81.5. Vassilopoulou-Sellin R, Palmer L, Taylor S, Cooksley CS. Incidence of breast carcinoma in women with thyroid carcinoma. Cancer. 1999; 85:696-705.6. Kuo JH, Chabot JA, Lee JA. Breast cancer in thyroid cancer survivors: An analysis of the Surveillance, Epidemiology, and End Results-9 database. Surgery. 2016; 159:23-9.7. An JH, Hwangbo Y, Ahn HY, et al. A Possible Association Between Thyroid Cancer and Breast Cancer. Thyroid : official journal of the American Thyroid Association. 2015; 25:1330-8.8. Subramanian S, Goldstein DP, Parlea L, et al. Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid : official journal of the American Thyroid Association. 2007; 17:1277-88.9. Goldman MB, Maloof F, Monson RR, Aschengrau A, Cooper DS, Ridgway EC. Radioactive iodine therapy and breast cancer. A follow-up study of hyperthyroid women. American journal of epidemiology. 1988; 127:969-80.10. Ron E, Curtis R, Hoffman DA, Flannery JT. Multiple primary breast and thyroid cancer. British journal of cancer. 1984; 49:87-92.11. Kumar A, Klinge CM, Goldstein RE. Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta. International journal of oncology. 2010; 36:1067-80.12. Vivacqua A, Bonofiglio D, Albanito L, et al. 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30. Molecular pharmacology. 2006; 70:1414-23.13. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. The Journal of clinical endocrinology and metabolism. 2008; 93:504-15.14. Consorti F, Di Tanna G, Milazzo F, Antonaci A. Nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer. World journal of surgical oncology. 2011; 9:88.15. Zhang L, Wu Y, Liu F, Fu L, Tong Z. Characteristics and survival of patients with metachronous or synchronous double primary malignancies: breast and thyroid cancer. Oncotarget. 2016.16. Tanaka H, Tsukuma H, Koyama H, Kinoshita Y, Kinoshita N, Oshima A. Second primary cancers following breast cancer in the Japanese female population. Japanese journal of cancer research : Gann. 2001; 92:1-8.17. Evans HS, Lewis CM, Robinson D, Bell CM, Moller H, Hodgson SV. Incidence of multiple primary cancers in a cohort of women diagnosed with breast cancer in southeast England. British journal of cancer. 2001; 84:435-40.18. Nielsen SM, White MG, Hong S, et al. The Breast-Thyroid Cancer Link: A Systematic Review and Meta-analysis. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2016; 25:231-8.19. Yane K, Kitahori Y, Konishi N, et al. Expression of the estrogen receptor in human thyroid neoplasms. Cancer letters. 1994; 84:59-66.20. Manole D, Schildknecht B, Gosnell B, Adams E, Derwahl M. Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. The Journal of clinical endocrinology and metabolism. 2001; 86:1072-7.21. Gogas J, Kouskos E, Tseleni-Balafouta S, et al. Autoimmune thyroid disease in women with breast carcinoma. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2001; 27:626-30.22. Hardefeldt PJ, Eslick GD, Edirimanne S. Benign thyroid disease is associated with breast cancer: a meta-analysis. Breast cancer research and treatment. 2012; 133:1169-77.23. Smyth PP. The thyroid, iodine and breast cancer. Breast cancer research : BCR. 2003; 5:235-8.24. Paes JE, Hua K, Nagy R, Kloos RT, Jarjoura D, Ringel MD. The relationship between body mass index and thyroid cancer pathology features and outcomes: a clinicopathological cohort study. The Journal of clinical endocrinology and metabolism. 2010; 95:4244-50.25. Fallahi B, Adabi K, Majidi M, et al. Incidence of second primary malignancies during a long-term surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment. Clinical nuclear medicine. 2011; 36:277-82.26. Lin CY, Lin CL, Huang WS, Kao CH. Risk of Breast Cancer in Patients with Thyroid Cancer Receiving or Not Receiving 131I Treatment: A Nationwide Population-Based Cohort Study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016; 57:685-90.
There are 1 citations in total.
Details
| Primary Language | English |
|---|---|
| Journal Section | Original research article |
| Authors | |
| Publication Date | March 14, 2019 |
| Submission Date | January 10, 2019 |
| Published in Issue | Year 2019 Volume: 52 Issue: 1 |